PTGX - NASDAQ
Protagonist Therapeutics, Inc.
$95.41
+1.5%Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
At a Glance
Live SnapshotProtagonist Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Protagonist Therapeutics, Inc. Cash Flow Statement
PTGX • NASDAQ
| Protagonist Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||
0.0 | 275.2M | -79M | -127.4M | -125.6M | -66.2M | -77.2M | -38.9M | -37M | -37.2M | -14.9M | -11.1M | |
0.0 | 2.9M | 3.3M | 3.4M | 2.8M | 2.6M | 2.5M | 527K | 406K | 317K | 247K | 258K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.4M | -775K | -658K | 0.0 | 151K | -8K | 0.0 | |
46M | 37.6M | 29.3M | 24.2M | 16.4M | 7.9M | 8.4M | 6.9M | 4.2M | 2.1M | 99K | 42K | |
-134.5M | -8.9M | -4.4M | -549K | 1.8M | 781K | -557K | 206K | 625K | 4.7M | 83K | 1.8M | |
146.2M | -122.6M | -19.5M | -7.8M | -3.3M | -19M | 26.1M | -18M | 35.6M | -112K | 52K | 1.3M | |
57.7M | 184.2M | -70.2M | -108.1M | -107.9M | -72.5M | -41.5M | -49.9M | 3.9M | -30M | -14.4M | -7.7M | |
INVESTING ACTIVITIES | ||||||||||||
-1.6M | -1.4M | -609K | -795K | -1.1M | -471K | -967K | -486K | -666K | -379K | -399K | -299K | |
(0.0) | (0.0) | (0.0) | -91.5M | (14.8M) | (90.5M) | (52.7M) | (0.0) | (0.0) | (32K) | (0.0) | (0.0) | |
-546.6M | -621.7M | -191M | -214.9M | -286.6M | -280M | -166.9M | -71.1M | -39.5M | -73.2M | -7.9M | (0.0) | |
498.8M | 323.6M | 152.4M | 307.1M | 271.8M | 189.5M | 114.2M | 73.8M | 56M | 14.2M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 91.5M | -14.8M | -90.5M | -52.7M | 2.7M | 16.5M | 32K | -7.9M | 0.0 | |
-49.3M | -299.5M | -39.3M | (91.5M) | -15.9M | -91M | -53.7M | (2.2M) | (15.8M) | -59.3M | -8.3M | -299K | |
FINANCING ACTIVITIES | ||||||||||||
23.3M | 26.5M | 132.1M | 14.6M | 123.8M | 255.4M | 34.5M | 23.2M | 64.5M | 83.6M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -10.5M | 9.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-479K | -600K | 38.4M | 4.3M | 6.1M | 2.8M | 1.8M | 934K | 1M | 151K | 57K | 3K | |
22.9M | 25.9M | 170.5M | 18.8M | 129.9M | 247.6M | 46M | 24.1M | 65.6M | 106.3M | 17.4M | 9M | |
CASH FLOW SUMMARY | ||||||||||||
-62K | 0.0 | 0.0 | -90K | -126K | 175K | -26K | -177K | 146K | 22K | -39K | -97K | |
31.1M | -89.5M | 61M | 2.1M | 6.1M | 84.4M | -49.2M | -23.8M | 85.4M | 17M | -5.3M | 864K | |
97.2M | 187M | 126M | 123.9M | 117.8M | 33.5M | 82.7M | 106.5M | 21.1M | 4.1M | 9.3M | 8.5M | |
128.4M | 97.5M | 187M | 126M | 123.9M | 117.8M | 33.5M | 82.7M | 106.5M | 21.1M | 4.1M | 9.3M | |
56.1M | 182.8M | -70.8M | -108.9M | -109M | -73M | -42.5M | -50.4M | 3.2M | -30.4M | -14.8M | -8M |
SEC Filings
PTGX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 06, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 06, 2025 | August 06, 2025 | 2025 |
Related Guides
Continue your PTGX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.